<DOC>
	<DOCNO>NCT00829530</DOCNO>
	<brief_summary>The objective study compare rate extent absorption Ramipril 10 mg capsule ( test ) versus Altace® ( reference ) , administer 1 x 10 mg capsule feed condition .</brief_summary>
	<brief_title>Ramipril 10 mg Capsule Healthy Subjects Under Fed Conditions</brief_title>
	<detailed_description>Detailed Description Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method Outcome : Confidence interval fell within 80-125 % therefore meet FDA Bioequivalence criterion ; drug relate , serious , unexpected adverse event report study .</detailed_description>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Male nonchildbearing potential female , light smoker nonsmoker 18 year age old . Capable consent Nonchildbearing potential female subject define follow : Postmenopausal state : absence menses 12 month prior drug administration hysterectomy bilateral oophorectomy least 6 month prior drug administration , Surgically sterile : hysterectomy , bilateral oophorectomy , tubule ligation least 6 month prior drud administration . Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical Sub Investigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant , specifically BUN , serum creatinine hyperkalemia . Positive test hepatitis B , hepatitis C , HIV screen . EcG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 100 140 mmHg , diastolic blood pressure low 60 90 mmHg , heart rate less 50 100 bpm ) change systolic blood pressure 20 mmHg , diastolic blood pressure 10mmHg passing supine ( least 5 minute ) stand position ( 13 minute ) , screen . BMI ≥30.0kg/m2 . History significant alcohol abuse within 6 month prior screen visit indication regular use 14 unit alcohol per week ( 1 Unit= 150 mL wine , 360 mL beer , 45 mL 40 % hard alcohol ) , positive alcohol breath test screening . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction heparin , ramipril , ACE inhibitor , relate drug . Use drug know induce hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoine , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion hte drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication ( include hormone replacement therapy ) within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Difficulty swallow study medication . Smoking 10 cigarette per day . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 30 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration . Intolerance venipunctures Clinically significant history renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Unable understand unwilling sign Informed Consent Form . Clinically significant history angioedema . History known presence volumedepletion ( diuretic , dialysis , gastrointestinal disease ) hypotension . History collagenvascular disease and/or renal disease . History ischemic heart disease , congestive heart failure , cerebrovascular disease . Breastfeeding subject . Positive urine pregnancy test screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>